Experts Fear Unethical Vaccine Trial in Africa Could Model US Studies Under RFK Jr
New revelations have sparked grave concerns among health experts that an unethical vaccine trial conducted in Guinea-Bissau may serve as a prototype for future studies under the administration of Robert F Kennedy Jr, the US Secretary of Health and Human Services and a longtime vaccine critic. The trial, which has been suspended pending review, involved Danish researchers whose work on vaccine effects has been questioned, and it is now at the center of a growing controversy over ethical standards in global health research.
Controversial Study and Its Implications
The trial in Guinea-Bissau aimed to examine the overall health effects of hepatitis B vaccines by vaccinating only half of the newborns at birth, despite an 18% prevalence rate of the disease in adults. Hepatitis B can lead to serious and sometimes fatal health consequences, making the study's design particularly alarming. Experts warn that this approach could have devastating repercussions, with Colette Delawalla, founder of the US nonprofit Stand Up for Science, stating, "We are fearful that this is a prototype for other studies." She compared the potential ethical lapses to the infamous Tuskegee experiment, suggesting such studies could become commonplace under Kennedy's leadership.
Danish Researchers and US Connections
The Danish researchers behind the trial, who have run the Bandim Health Project in Guinea-Bissau for 48 years, are now facing scrutiny over their previous work. A recent study published in Vaccine highlighted instances where these researchers conducted studies but released only partial results or none at all. Their ties to the current US administration are deep: Kennedy has cited researcher Peter Aaby as influential in his views on vaccines, while Christine Stabell Benn, another researcher, served on a key immunization advisory committee. Stabell Benn also collaborated with Tracy Beth Høeg, a top FDA official who advocates for reducing "unnecessary" vaccines.
Ethical Challenges in Guinea-Bissau
The ethical landscape in Guinea-Bissau complicates the trial further. Magda Robalo, former minister of health in Guinea-Bissau, noted that informed consent is extremely difficult due to low literacy rates and language barriers. For example, the local creole term for hepatitis B, "febri amarelu," also refers to yellow fever, creating confusion. Robalo emphasized, "Guinea-Bissau does not have a single credible institution in public health research at this point in time," leading to potential conflicts of interest as local researchers often work with Bandim. The ethics committee is seen as a "friends club" that charges fees for reviews, raising concerns about impartiality.
Global and US Responses
In response to public outcry, the University of Southern Denmark has paused all work related to the study while it undergoes review. Ole Skøtt, dean of health sciences, has contacted the WHO's research ethics review committee for an independent evaluation. Meanwhile, the US House Committee on Energy and Commerce expressed concerns in a letter, calling the trial "ethically disturbing and scientifically unsound" and questioning the CDC's role in funding it. The WHO's director-general, Tedros Adhanom Ghebreyesus, stated it was "unethical to proceed with this study," and Guinea-Bissau's foreign minister confirmed the trial would not happen.
Broader Impact and Future Directions
The trial has resonated across Africa, with countries working to improve their research capabilities and reduce dependency on Global North institutions. African health officials, including those at the Africa CDC, emphasize the priority should be rolling out hepatitis B vaccines to all newborns as soon as possible. The US allocated $1.6 million to the trial, with matching funds from foundations, leading Delawalla to remark that this money could vaccinate every newborn in Guinea-Bissau for a decade. As the study remains paused, the debate highlights critical issues in ethical research and vaccine policy under the new US administration.
